Edition:
United States

Profile: OncoSec Medical Inc (ONCS.PH)

ONCS.PH on Philadelphia Stock Exchange

2.27USD
8 Aug 2019
Change (% chg)

-- (--)
Prev Close
$2.27
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
351
52-wk High
$19.50
52-wk Low
$2.11

OncoSec Medical Incorporated, incorporated on February 8, 2008, is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer.

The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, the Company is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer.

The Company's ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses. The Company's product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, Interleukin 12 (IL-12), which is delivered into the tumor through in vivo electroporation.

Company Address

OncoSec Medical Inc

24 N Main St
PENNINGTON   NJ   08534-2218
P: +1858.2107333

Company Web Links